Brentuximab vedotin (Adcetris) is indicated for treating relapsed or refractory CD30‑positive Hodgkin lymphoma in adults:
after autologous stem cell transplant or
after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option
at increased risk of relapse or progression after autologous stem cell transplant.
The recommended dose is 1.8 mg/kg administered by intravenous infusion over 30 minutes every 3 weeks.
The price of brentuximab vedotin is £2,500 for a 50‑mg vial (excluding VAT; British national formulary edition 69). The company has a commercial arrangement. This makes brentuximab vedotin available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.'